U.S. In-Vitro Fertilization Services Market By Gender, (Male Infertility, Female Infertility, and Others), Procedure, (ICSI IVF, Non ICSI IVF, and IUI), Cycle Type, (IVF Cycle and IUI Cycle), End User, (Fertility Clinics, Hospitals, Surgical Centers, and Clinical Research Institutes), and Offering, (IVF Drugs, IVF Media and Reagents, and IVF And IUI Services): Opportunity Analysis And Industry Forecast, 2025-2032

U.S. in-vitro fertilization services Market Research - 2032

The U.S. in-vitro fertilization services market was valued at $5,910.98 million in 2024 and is projected to reach $13,944.38 million by 2032, registering a CAGR of 11.3% from 2025 to 2032. According to a 2024 article by the Centers for Disease Control and Prevention (CDC), approximately 20% of married women of childbearing age in the U.S. have trouble in conceiving after one year of trying. This increasing incidence of infertility has led to heightened awareness and adoption of IVF services.

In vitro fertilization (IVF) is an assisted reproductive technology (ART) in which eggs are retrieved from the ovaries and fertilized with sperm in a laboratory setting, with the resulting embryos transferred into the uterus. IVF services are widely used in the U.S. to address infertility issues arising from factors such as advanced maternal age, ovulation disorders, endometriosis, blocked fallopian tubes, male factor infertility, or unexplained infertility. Accurate diagnostic assessments and personalized treatment plans are central to improving IVF success rates. Early intervention and advanced fertility preservation methods are helping individuals and couples pursue parenthood, while increasing awareness, rising infertility rates, delayed parenthood, and broader insurance coverage are driving the demand for IVF services across the U.S.

Key Takeaways

• By gender, the female segment was the highest contributor to the U.S. In-Vitro Fertilization Services Market in 2024 and is expected to register the highest CAGR during the forecast period.
• By procedure, the ICSI IVF segment was the highest contributor to the U.S. In-Vitro Fertilization Services Market in 2024 and is expected to register the highest CAGR during the forecast period.
• By cycle type, the IVF cycle segment was the highest contributor to the U.S. In-Vitro Fertilization Services Market in 2024 and is expected to register the highest CAGR during the forecast period.
• By end user, the fertility centers segment was the highest contributor to the U.S. In-Vitro Fertilization Services Market in 2024 and is expected to register the highest CAGR during the forecast period.
• By offering, the IVF and IUI services segment was the highest contributor to the U.S. In-Vitro Fertilization Services Market in 2024 and is expected to register the highest CAGR during the forecast period.

Market Dynamics

The U.S. in-vitro fertilization (IVF) services market is witnessing robust growth, driven by a combination of rising infertility rates, delayed parenthood, favorable insurance coverage, and advancements in assisted reproductive technologies. Increasing lifestyle-related disorders such as obesity, diabetes, and polycystic ovary syndrome (PCOS), along with rising maternal age, are contributing to infertility challenges, thereby fueling demand for IVF services. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 5 married women of childbearing age in the U.S. face difficulties conceiving, underlining the need for advanced fertility treatments.

Further, government initiatives and supportive regulations further strengthen the U.S. In-Vitro Fertilization Services Market. Several states in the U.S. have introduced mandates requiring insurance providers to cover infertility treatments, including IVF, which has significantly improved accessibility. National organizations such as the American Society for Reproductive Medicine (ASRM) continue to publish clinical practice guidelines to ensure ethical standards, patient safety, and success rate transparency across fertility clinics. These guidelines also highlight the importance of advanced diagnostic testing and technologies like preimplantation genetic testing (PGT), which improves outcomes by identifying chromosomal abnormalities before embryo transfer.

In addition, technological advancements are revolutionizing the industry. Innovations such as time-lapse embryo imaging, artificial intelligence (AI)-based embryo selection, and cryopreservation techniques are improving success rates while reducing risks. Egg freezing and fertility preservation services are gaining popularity among younger women choosing to delay pregnancy due to career, lifestyle, or medical reasons. These advancements not only improve patient confidence but also expand the demographic base for IVF services.

The U.S. In-Vitro Fertilization Services Market is also benefiting from rising awareness campaigns led by fertility clinics, non-profits, and healthcare organizations that focus on infertility education, early diagnosis, and available treatment options. Increasing openness about reproductive health in the U.S., supported by social media and public figures, has reduced stigma and encouraged more couples and individuals to seek IVF treatment.

However, challenges persist. High treatment costs per cycle, limit accessibility for uninsured patients and those in states without mandated coverage. Emotional and psychological stress associated with multiple cycles and uncertain outcomes can also deter patients. Furthermore, ethical debates surrounding embryo selection, third-party reproduction (donor eggs/sperm, surrogacy), and genetic testing present ongoing concerns in the U.S. regulatory landscape.

However, the U.S. IVF services market holds significant opportunities. Growing adoption of personalized medicine, integration of genetic testing, and the increasing role of AI in embryo selection are expected to improve success rates and reduce costs over time. Expansion of fertility benefits offered by employers, coupled with growing demand for fertility preservation services, further enhances growth potential. With rising R&D investment and a highly developed healthcare infrastructure, the U.S. remains one of the most attractive and fastest-evolving markets for IVF services worldwide.

Segmental Overview

The U.S. in-vitro fertilization services market is segmented on the basis of gender, procedure, cycle type, end user, and offering. On the basis of gender, the market is divided into male infertility, female Infertility, and others. On the basis of procedure, the U.S. In-Vitro Fertilization Services Market is divided into ICSI IVF, Non ICSI IVF, and IUI. On the basis of cycle type, the market is divided into IVF cycle and IUI cycle. IVF cycle is further divided into fresh IVF cycle, thawed IVF cycles, and donor egg IVF cycles. On the basis of end user, the market is divided into fertility clinics, hospitals, surgical centers, and clinical research institutes. On the basis of offering, the U.S. In-Vitro Fertilization Services Market is divided into IVF drugs, IVF media and reagents, and IVF and IUI services.

By Gender

On the basis of gender, the female segment was the major revenue contributor in 2024 and is expected to witness a significant CAGR during the forecast period. This growth is attributed to various medical, social, and lifestyle factors. Rising maternal age due to delayed family planning for career or educational purposes, increasing prevalence of polycystic ovary syndrome (PCOS), and age-related fertility decline have significantly contributed to the growing demand for IVF treatments among women..

By Procedure

On the basis of procedure, the ICSI IVF segment was the major revenue contributor in 2024 and is expected to witness a significant CAGR during the forecast period. The dominance of this segment is attributed to the rising prevalence of male infertility, characterized by low sperm count, reduced motility, or abnormal morphology. ICSI is increasingly preferred as it directly injects a single sperm into the egg, thereby offering higher fertilization success rates in cases where conventional IVF may fail.

By Cycle Type

On the basis of cycle type, the IVF segment was the major revenue contributor in 2024 and is expected to witness a significant CAGR during the forecast period. IVF cycles provide enhanced control over fertilization, embryo selection, and genetic screening, leading to improved pregnancy outcomes, especially in cases of advanced maternal age, recurrent implantation failure, or unexplained infertility. Moreover, advancements such as frozen embryo transfers and preimplantation genetic testing (PGT) are boosting the adoption of IVF over other cycle types such as IUI.

By End User

On the basis of end user, the fertility clinics segment was the major revenue contributor in 2024 and is expected to witness a significant CAGR during the forecast period. Specialized fertility centers are increasingly preferred as they offer advanced infrastructure, skilled embryologists, and cutting-edge technologies such as time-lapse embryo monitoring, vitrification, and genetic testing. These clinics provide comprehensive and personalized treatment options, leading to higher success rates compared to general hospitals or other healthcare settings.

By Offering

On the basis of offering, the IVF and IUI services segment was the major revenue contributor in 2024. This is attributed to rising prevalence of infertility, driven by factors such as obesity, diabetes, thyroid dysfunction, environmental pollutants, sexually transmitted infections, and age-related fertility decline, which increases the demand for these services.

Competition Analysis

Competitive analysis and profiles of the major players in the  U.S. in-vitro fertilization services market include New Hope Fertility Clinic, Colorado Center for Reproductive Medicine, Pacific Fertility Center, Houston Fertility Institute, Columbia University Fertility Center, Cleveland Clinic Fertility Center, Fertility Centers of Illinois, Shady Grove Fertility Center, Mayo Clinic Fertility Center, and Reproductive Medicine Associates. Key players operating in the U.S. In-Vitro Fertilization Services Market have adopted various strategies such as business expansion and acquisition as their key strategy to expand their product portfolio.

Recent Developments in U.S. in-vitro fertilization services Industry

• In July 2023, Colorado Center for Reproductive Medicine announced expansion to South Florida with a new state-of-art fertility clinic and in vitro fertilization (IVF) lab in Miami. The clinic is located in the Esplanade at Aventura development at 19505 Biscayne Blvd., Suite 2230, in Miami, FL, 33180.
• In April 2023, Colorado Center for Reproductive Medicine announced the acquisition of Virginia Beach-based fertility clinic The New Hope Center for Reproductive Medicine. The acquisition further expands CCRM Fertility’s east coast footprint, offering more convenient access to world-class fertility treatments and care, and leading success rates through comprehensive testing, superior labs, and in-house genetics and research.
• In May 2025, Colorado Center for Reproductive Medicine announced the opening of its newest state-of-the-art clinic in Chicago on May 19th, marking a major step in expanding its commitment to accessible, high-quality reproductive care across the country.
• In September 2024, Boston IVF, a wholly owned subsidy of Reproductive Medicine Associates, announced the opening of its newest fertility center in Concord, Massachusetts.
• In August 2023, Colorado Center for Reproductive Medicine announced the addition of two new IVF centers in Chicago, Dr. Charles Miller leads two Chicago-area locations and provides cutting-edge fertility treatments, including in vitro fertilization (IVF), fertility preservation and reproductive surgery.

^*Terms and Conditions Apply